AQST
Price
$7.08
Change
+$0.07 (+1.00%)
Updated
Oct 17 closing price
Capitalization
856.49M
23 days until earnings call
ETON
Price
$18.18
Change
-$0.16 (-0.87%)
Updated
Oct 17 closing price
Capitalization
487.54M
25 days until earnings call
Interact to see
Advertisement

AQST vs ETON

Header iconAQST vs ETON Comparison
Open Charts AQST vs ETONBanner chart's image
Aquestive Therapeutics
Price$7.08
Change+$0.07 (+1.00%)
Volume$3.33M
Capitalization856.49M
Eton Pharmaceuticals
Price$18.18
Change-$0.16 (-0.87%)
Volume$308.32K
Capitalization487.54M
AQST vs ETON Comparison Chart in %
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ETON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AQST vs. ETON commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AQST is a Hold and ETON is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (AQST: $7.08 vs. ETON: $18.18)
Brand notoriety: AQST and ETON are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AQST: 101% vs. ETON: 101%
Market capitalization -- AQST: $856.49M vs. ETON: $487.54M
AQST [@Pharmaceuticals: Generic] is valued at $856.49M. ETON’s [@Pharmaceuticals: Generic] market capitalization is $487.54M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.85B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.96B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AQST’s FA Score shows that 0 FA rating(s) are green whileETON’s FA Score has 1 green FA rating(s).

  • AQST’s FA Score: 0 green, 5 red.
  • ETON’s FA Score: 1 green, 4 red.
According to our system of comparison, ETON is a better buy in the long-term than AQST.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AQST’s TA Score shows that 3 TA indicator(s) are bullish while ETON’s TA Score has 4 bullish TA indicator(s).

  • AQST’s TA Score: 3 bullish, 4 bearish.
  • ETON’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both AQST and ETON are a bad buy in the short-term.

Price Growth

AQST (@Pharmaceuticals: Generic) experienced а +8.26% price change this week, while ETON (@Pharmaceuticals: Generic) price change was -7.53% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.79%. For the same industry, the average monthly price growth was +4.23%, and the average quarterly price growth was +51.45%.

Reported Earning Dates

AQST is expected to report earnings on Nov 10, 2025.

ETON is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.79% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AQST($856M) has a higher market cap than ETON($488M). AQST YTD gains are higher at: 98.876 vs. ETON (36.486). ETON has higher annual earnings (EBITDA): 1.84M vs. AQST (-47.5M). AQST has more cash in the bank: 60.5M vs. ETON (25.4M). ETON has less debt than AQST: ETON (30.7M) vs AQST (40.3M). ETON has higher revenues than AQST: ETON (58.2M) vs AQST (44.1M).
AQSTETONAQST / ETON
Capitalization856M488M175%
EBITDA-47.5M1.84M-2,576%
Gain YTD98.87636.486271%
P/E RatioN/A124.00-
Revenue44.1M58.2M76%
Total Cash60.5M25.4M238%
Total Debt40.3M30.7M131%
FUNDAMENTALS RATINGS
AQST vs ETON: Fundamental Ratings
AQST
ETON
OUTLOOK RATING
1..100
2680
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
86
Overvalued
PROFIT vs RISK RATING
1..100
10038
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
3640
P/E GROWTH RATING
1..100
1006
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AQST's Valuation (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for ETON (86). This means that AQST’s stock grew somewhat faster than ETON’s over the last 12 months.

ETON's Profit vs Risk Rating (38) in the Pharmaceuticals Major industry is somewhat better than the same rating for AQST (100). This means that ETON’s stock grew somewhat faster than AQST’s over the last 12 months.

ETON's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as AQST (100). This means that ETON’s stock grew similarly to AQST’s over the last 12 months.

AQST's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as ETON (40). This means that AQST’s stock grew similarly to ETON’s over the last 12 months.

ETON's P/E Growth Rating (6) in the Pharmaceuticals Major industry is significantly better than the same rating for AQST (100). This means that ETON’s stock grew significantly faster than AQST’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AQSTETON
RSI
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
82%
Declines
ODDS (%)
Bearish Trend 19 days ago
88%
Bearish Trend 2 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
71%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ETON
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RRGAX7.490.05
+0.67%
DWS RREEF Global Real Estate Secc A
SROAX13.960.09
+0.65%
Calamos Antetokounmpo Sustainable Eqs A
SWANX25.770.16
+0.62%
Schwab Core Equity
RIGKX16.820.03
+0.18%
Victory RS International R
FRIOX11.98N/A
N/A
Fidelity Advisor Real Estate Income C

AQST and

Correlation & Price change

A.I.dvisor tells us that AQST and DRRX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AQST and DRRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AQST
1D Price
Change %
AQST100%
+1.00%
DRRX - AQST
30%
Poorly correlated
N/A
NBIX - AQST
29%
Poorly correlated
+1.87%
TLRY - AQST
28%
Poorly correlated
+1.30%
ESPR - AQST
28%
Poorly correlated
+3.77%
ETON - AQST
27%
Poorly correlated
-0.87%
More

ETON and

Correlation & Price change

A.I.dvisor indicates that over the last year, ETON has been loosely correlated with MDGL. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ETON jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ETON
1D Price
Change %
ETON100%
-0.87%
MDGL - ETON
34%
Loosely correlated
-0.73%
VKTX - ETON
31%
Poorly correlated
-3.44%
LBTSF - ETON
30%
Poorly correlated
N/A
ARRY - ETON
30%
Poorly correlated
-0.17%
FDMT - ETON
29%
Poorly correlated
-2.48%
More